Class-action accuses Takeda of ‘pay-for-delay’ deal with Par
01-07-2021
Takeda ‘to sell OTC business in Europe’ to fund Shire acquisition
31-10-2018
timarbaev / iStockphoto.com
Japan-based Takeda Pharmaceutical has persuaded the European Union Intellectual Property Office (EUIPO) that an applied-for trademark would be confused with its own earlier-registered mark.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Takeda Pharmaceutical, Nikken International, Kenzen, European Union Intellectual Property Office, trademark opposition, cardiovascular
